CJC-1295 represents a synthetically engineered growth hormone-releasing hormone (GHRH) analogue that has garnered considerable attention in peptide research communities due to its capacity to interact with GHRH receptors through markedly prolonged binding kinetics. In contrast to endogenous GHRH(1–44), which undergoes rapid enzymatic degradation by plasma dipeptidyl peptidase IV (DPP-IV), CJC-1295 features deliberate amino acid modifications and—in its DAC-conjugated formulation—incorporates drug affinity complex technology enabling covalent albumin attachment. This extends its functional half-life from mere minutes to multiple days in laboratory animal models. Such structural sophistication has positioned CJC-1295 among the most extensively investigated GHRH analogues in experimental settings examining pulsatile growth hormone (GH) secretion, IGF-1 signaling cascades, and associated metabolic pathways.
Investigation of CJC-1295 encompasses two primary forms: CJC-1295 with DAC (drug affinity complex) and CJC-1295 without DAC (commonly termed Modified GRF(1–29) or Mod-GRF). These variants exhibit distinct pharmacokinetic characteristics relevant to investigators examining GH secretagogue biology, making comprehension of their mechanistic distinctions critical for rigorous preclinical experimental design. This comprehensive research guide synthesizes available preclinical evidence, receptor biochemistry, and structural chemistry to support researchers working with CJC-1295 in 2026. For further context on GHRH analogue research, see the CJC-1295 peptide research guide.
Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied. CJC-1295 is a research compound not intended for human or animal use.
Frequently Asked Questions
What is CJC-1295 and how does it differ from native GHRH?
CJC-1295 is a 30-amino acid synthetic analogue of endogenous growth hormone-releasing hormone (GHRH). Its molecular architecture diverges from natural GHRH(1–44) through targeted amino acid substitutions at positions 2, 8, 15, and 27, which collectively impart resistance to DPP-IV-mediated proteolytic cleavage. This modification substantially extends the compound's active half-life in preclinical experimental systems. The DAC-conjugated variant forms an additional covalent linkage with circulating albumin, prolonging receptor engagement duration beyond that observed with the No-DAC formulation.
What is the difference between CJC-1295 with DAC and CJC-1295 without DAC?
CJC-1295 with DAC contains a maleimido-propionic acid (MPA) linker—the Drug Affinity Complex component—facilitating covalent attachment to endogenous albumin molecules. Laboratory animal studies have documented half-lives approximating 5–8 days for this DAC-bearing variant. In contrast, CJC-1295 without DAC (Mod-GRF(1–29)) lacks this albumin-binding moiety and demonstrates a substantially abbreviated half-life of roughly 30 minutes, yielding a more pronounced, pulsatile GH release profile in experimental animal models.
How does CJC-1295 interact with the GHRH receptor?
CJC-1295 engages the GHRH receptor (GHRHR), classified as a class B G protein-coupled receptor predominantly expressed on anterior pituitary somatotroph cells. Ligand-receptor interaction activates adenylyl cyclase through Gs protein coupling, elevating intracellular cyclic AMP (cAMP) concentrations and subsequently triggering calcium-dependent exocytosis of GH-containing secretory vesicles. Preclinical evidence indicates CJC-1295 activates this signaling cascade with enhanced affinity and extended duration relative to native GHRH.
What preclinical models have been used to study CJC-1295?
Published preclinical investigations have employed rodent experimental systems (predominantly rats and mice) alongside non-human primate models to elucidate CJC-1295's pharmacokinetic and pharmacodynamic characteristics. Research protocols have examined GH pulse amplitude, serum IGF-1 concentrations, and downstream signaling cascades within these model organisms. Additionally, in vitro receptor binding assays have been utilized to quantify affinity parameters at the GHRHR.
Is CJC-1295 often combined with other secretagogues in research?
Affirmative. Preclinical investigations have routinely co-administered CJC-1295 alongside ghrelin receptor agonists including ipamorelin to examine synergistic GH release mediated through dual receptor pathway stimulation. The CJC-1295 and ipamorelin pairing targets complementary receptor systems—GHRHR and the ghrelin receptor (GHSR-1a) respectively—representing a well-documented experimental combination throughout the preclinical GH biology literature.
What does the IGF-1 axis have to do with CJC-1295 research?
Growth hormone released following GHRHR activation stimulates hepatic synthesis of insulin-like growth factor 1 (IGF-1). Preclinical CJC-1295 studies routinely quantify serum IGF-1 as a downstream indicator of GHRHR engagement and sustained GH secretory activity. Elevated IGF-1 levels in animal models following CJC-1295 administration have been documented across numerous published investigations, furnishing an indirect measure of GHRH axis activation.
What is Mod-GRF(1–29) and how does it relate to CJC-1295?
Mod-GRF(1–29) serves as the prevailing research designation for CJC-1295 without DAC. This terminology references the initial 29 amino acids of GHRH, incorporating four strategic amino acid substitutions conferring DPP-IV enzymatic resistance. It lacks the albumin-binding maleimide linker characteristic of the DAC variant, resulting in a compressed active duration. Both molecular forms engage the GHRHR yet display divergent pharmacokinetic properties in preclinical experimental systems.
GHRH Receptor Biology: The Molecular Foundation
Understanding CJC-1295's research utility requires foundational knowledge of GHRH receptor system biology. The GHRHR constitutes a class B (secretin family) G protein-coupled receptor with predominant expression on anterior pituitary somatotroph cells. Following ligand binding, this receptor couples to the stimulatory Gs alpha subunit, activating adenylyl cyclase and precipitating an intracellular cAMP surge. This second-messenger cascade activates protein kinase A (PKA), which phosphorylates critical transcription factors including cAMP response element-binding protein (CREB), ultimately driving both immediate GH exocytosis and sustained GH gene transcription.
Endogenous GHRH undergoes pulsatile secretion from the hypothalamic arcuate nucleus, traversing the hypothalamic-pituitary portal circulation to reach somatotrophs. However, circulating free GHRH exhibits pronounced susceptibility to proteolytic cleavage at the His2-Ala3 peptide bond by DPP-IV, rendering it biologically inert within minutes. CJC-1295 circumvents this degradation pathway through D-alanine substitution at position 2, combined with modifications at positions 8, 15, and 27 that collectively confer enzymatic stability while preserving receptor binding affinity.
Somatotroph Physiology and Pulsatility
A fundamental principle in GHRH research concerns GH pulsatility. Growth hormone secretion does not occur tonically—its release follows ultradian rhythmic patterns orchestrated by the interplay between stimulatory GHRH and inhibitory somatostatin (SST). High-amplitude GH pulses, rather than sustained low-level secretion, appear essential for mediating numerous downstream biological effects, including robust IGF-1 production. CJC-1295 without DAC, given its abbreviated half-life, is hypothesized to preserve or augment pulsatile GH dynamics more effectively than the prolonged-acting DAC variant, which tends toward more continuous GH elevation in animal experimental systems. Investigators studying GH pulse biology typically select between the two CJC-1295 formulations based on whether pulsatile or sustained GH secretion profiles align with their experimental objectives.
Structural Chemistry: DAC Technology and Albumin Binding
The Drug Affinity Complex (DAC) system embodies a notable biochemical innovation in peptide pharmacokinetics research. Within CJC-1295 with DAC, a maleimido-propionic acid (MPA) moiety is conjugated to the lysine residue at position 29 via amide linkage. Upon plasma introduction, this reactive maleimide undergoes Michael addition with the free thiol group of cysteine-34 on serum albumin—the most abundant plasma protein, exhibiting a half-life approximating 19 days in humans and 2–3 days in rodents.
By leveraging albumin's extended circulatory lifespan, CJC-1295 with DAC achieves plasma half-lives approaching 5–8 days in preclinical rodent investigations. This represents a multi-order-of-magnitude increase versus native GHRH or even the No-DAC modified analogue. From an experimental design perspective, this prolonged activity window permits investigators to examine GH axis responses across extended observation periods without repeated administration, streamlining experimental protocols.
Comparative Structural Summary
| Feature | CJC-1295 with DAC | CJC-1295 No DAC (Mod-GRF) |
|---|---|---|
| Amino acid sequence | Modified GHRH(1–29) + DAC linker | Modified GHRH(1–29) |
| DPP-IV resistance | Yes | Yes |
| Albumin binding | Yes (covalent, via MPA) | No |
| Approximate half-life (preclinical) | 5–8 days | ~30 minutes |
| GH secretion pattern (observed) | Sustained / blunted pulse | Acute pulsatile amplification |
| IGF-1 elevation duration | Prolonged (days) | Hours |
| Primary research application | Long-term GH axis studies | Pulsatile GH dynamics studies |
Key Preclinical Study Findings
Foundational pharmacokinetic characterization of CJC-1295 was published by Jetté and colleagues in 2005 within the Journal of Clinical Endocrinology & Metabolism. This investigation examined GH and IGF-1 responses in healthy adult subjects and animal models following CJC-1295 with DAC administration. Within the animal component, dose-dependent increases in mean plasma GH concentrations were documented, with sustained IGF-1 elevations persisting up to 14 days following single administration in certain models. These observations established CJC-1295's standing as a long-acting GHRH analogue of substantial research significance.
GH Pulse Amplitude and Frequency
Subsequent rodent investigations have characterized how CJC-1295 No DAC modulates GH pulse dynamics. In these experimental systems, No-DAC variant administration correlated with increased GH pulse amplitude without corresponding significant alterations in pulse frequency, consistent with established GHRH mechanistic action (primarily amplifying pulse height rather than modifying pulse timing). This preservation of pulsatile architecture interests researchers examining physiological versus pharmacological consequences of GHRH axis stimulation.
Synergy with Ghrelin Receptor Agonists
A consistently replicated observation throughout preclinical literature involves synergistic GH-releasing effects when GHRH analogues are co-administered with ghrelin receptor (GHSR-1a) agonists such as ipamorelin. Ipamorelin research has established that ghrelin-pathway activation not only independently stimulates GH release but also potentiates GHRH-driven secretion by sensitizing somatotrophs to GHRH stimulation. When CJC-1295 and ipamorelin are combined in rodent models, GH responses surpass those produced by either compound individually—a finding establishing this combination as a frequently investigated pairing in preclinical GH biology research. More information on related peptide research tools is available at SourcePeptides.co.
IGF-1 Axis Downstream Effects
Multiple rodent studies have documented that sustained GHRHR engagement by CJC-1295 with DAC produces prolonged serum IGF-1 elevations, reflecting continuous hepatic GH signaling activity. The IGF-1 receptor (IGF-1R) functions as a receptor tyrosine kinase mediating numerous GH anabolic and metabolic downstream effects in tissue model systems. Researchers have utilized CJC-1295-driven IGF-1 elevation as an experimental platform for investigating IGF-1R signaling cascades, including PI3K/Akt and MAPK/ERK pathways, across various tissue types. This establishes CJC-1295 as a versatile research tool for investigating not merely pituitary biology but also peripheral GH-IGF axis signaling networks.
CJC-1295 in the Context of Broader GH Secretagogue Research
CJC-1295 does not function in isolation within the GH biology research landscape. Understanding its position relative to other secretagogue classes proves important for experimental design. The GH secretagogue family broadly encompasses GHRH analogues (of which CJC-1295 represents the most extensively studied), ghrelin mimetics (including ipamorelin and GHRP-6), and somatostatin inhibitors. Each class engages distinct receptor populations and produces subtly different GH secretion profiles in preclinical model systems.
For researchers interested in the intersection between GH axis stimulation and broader metabolic peptide biology, it merits noting that other peptide classes studied in related metabolic research contexts activate entirely separate receptor systems yet share overlapping research themes around metabolic signaling and tissue biology. Understanding these distinctions assists investigators in designing hypothesis-driven experiments isolating the specific contribution of GHRH axis activity. For additional research on tissue repair peptides, see GHK-Cu research applications.
Combination Research: CJC-1295 + Ipamorelin
As previously noted, the CJC-1295 / ipamorelin combination ranks among the most consistently studied peptide pairings in GH secretagogue literature. Mechanistically, the rationale is straightforward: GHRH (via CJC-1295) maximally activates the Gs/cAMP pathway in somatotrophs, while ghrelin agonists (via ipamorelin) concurrently suppress somatostatin tone and activate a distinct Gq-coupled calcium signaling pathway. Convergence of these two pro-secretory mechanisms produces synergistic GH release unattainable by either compound alone. Researchers designing studies of pituitary physiology, GH pulse dynamics, or IGF-1 axis responses frequently utilize this combination for its robust and reproducible preclinical pharmacology.
Choosing Between CJC-1295 Variants for Research
Choose CJC-1295 with DAC if...
- The research objective necessitates sustained, multi-day GH axis stimulation without frequent re-administration
- The experimental model involves longitudinal tracking of IGF-1 as a downstream biomarker over days to weeks
- The investigator is examining chronic GHRHR engagement and potential receptor regulation or desensitization dynamics
- Simplified dosing protocols are required due to animal model constraints
Choose CJC-1295 No DAC if...
- The research question centers on pulsatile GH release physiology and preservation of natural GH rhythm architecture
- Acute GH pulse amplitude studies constitute the primary endpoint
- The compound is being combined with ipamorelin or another GHSR agonist to investigate synergistic pulsatile GH dynamics
- Shorter experimental windows are planned and rapid clearance between sampling periods is desirable
Laboratory Handling and Reconstitution Considerations
For researchers preparing CJC-1295 for preclinical in vitro or in vivo model applications, standard peptide handling practices apply. CJC-1295 is typically supplied as lyophilized powder requiring reconstitution in appropriate aqueous vehicle. The selection of reconstitution vehicle significantly affects peptide stability, sterility, and reliability of preclinical results. Using research-grade bacteriostatic water minimizes microbial contamination risk during multi-use reconstitution protocols. Storage of lyophilized CJC-1295 at −20°C represents standard practice, with reconstituted solutions typically maintained at 2–8°C and utilized within defined timeframes according to laboratory SOPs.
The DAC variant warrants particular care during reconstitution, as the maleimide linker exhibits reactivity and may demonstrate sensitivity to conditions promoting premature albumin binding or hydrolysis prior to in vivo application. Researchers are advised to consult published protocols and work under conditions minimizing oxidative stress to the compound.
Final Takeaway: CJC-1295 as a GHRH Research Tool
CJC-1295 represents one of the most pharmacologically refined GHRH analogues available for preclinical research applications. Its two principal variants—the long-acting DAC form and the shorter-acting No-DAC (Mod-GRF) form—furnish investigators with flexible tools for studying GHRH receptor biology across diverse experimental timescales and GH secretion models. The substantial preclinical literature documenting its IGF-1-elevating properties, synergy with ghrelin-pathway agonists, and well-characterized albumin-binding pharmacokinetics establishes CJC-1295 as an indispensable reference compound for researchers studying the hypothalamic-pituitary GH axis in 2026. Whether utilized alone or in combination with ipamorelin, CJC-1295 continues generating meaningful preclinical insights into fundamental growth hormone secretion biology.
Sources & Further Reading
- Jetté L et al. — "hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog" — Endocrinology (2005)
- PubMed Search — GHRH receptor somatotroph biology — PubMed (Multiple Years)
- Tannenbaum GS, Bowers CY — "Interactions of growth hormone secretagogues and growth hormone-releasing hormone/somatostatin" — Endocrine (2001)
- Alba M et al. — "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse" — American Journal of Physiology (2006)
- PubMed Search — Ipamorelin and GHRH synergy in growth hormone secretion — PubMed (Multiple Years)
Disclaimer: This article is for informational and research purposes only. The products mentioned are intended for laboratory and research use only and are not for human consumption. These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.
Originally published at https://www.sourcepeptides.co/2026/07/31/cjc-1295-peptide-research-guide-mechanisms-ghrh-biology-preclinical-study-findings-2026/.
Top comments (0)